drugset / Trial / NCT05333588
The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.
NaSingle-groupOpen-labelTreatment
Summary
The study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy for patients with maligant glioblastoma multiforme. Autologous TiLs should be given by intravenous infusion after 5 days of lymphodepletion treatment.
Timeline
- Start
- 2022-02-15
- Primary completion
- 2024-02-15
- Completion
- 2025-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 1e+09 cells | Intravenous |
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 5e+10 cells | Intravenous |